March 25, 2015
The Company’s business operations consist of doing business in the cell repair and cell replacement for Equine stock
only at present, but we are pursuing FDA approval for existing and modified products to be used for the repair of the
Human Body. It is estimated that this process will take up to six months assuming a problem-free time-line and funds
available to complete. Its products have been successfully utilised for the repair of horses tendons and have the
added bonus of being patented worldwide, with an exclusive licence in the name of the Company for equine and
human applications. In October 2013 we had to cease trialing the process due to lack of available and sustainable
funds. The new initiative to generate investment into the company will allow us to recommence these trials and move
towards selling the equine product on the open market. As a result, the Company is still in development and approval
stage.
Whilst we have raised the previosly estimated $2million required to obtain US Food and Drug Administration approval
of the patented process for humans and to make the product available to our targeted markets our due diligence has
been completed and we are close to finalising the funding.[color=green][/color] The new loan investment in the Company would allow
trials to recommence. The delay in receiving the new funding has prevented us from pursuing the FDA approval,
appointing our preferred investor relations and public relations consultants and commissioning the new website.
We have also released into the market substantial amounts of Common stock that had previously been tied up in
convertible loan notes. Further increases in the authorized Common Stocks are not deemed necessary at present.
Therapy Cells, Inc. (PINKSHEETS: TCEL) FULL REPORT
Jan. 31st, 2014 Chief Analyst Mark Bonacci
The company’s new approach to cell growth has already been applied to the repair of tendons and joints. The technology has also been applied to the re-growth of pancreas and heart tissue. Rejection does not occur as the new cells are from that individual and are recognized by the body as non foreign. It is believed that this new method of cell growth will be successfully used for cell and organ repair in many parts of the human body.
Therapy Cells has developed a novel and highly efficient method of growing tendon and articular cartilage for auto transplantation into individual, affected patients. The company has developed new cell theory that dispenses with the notion that cells cannot divide once they are fully mature. TCEL has shown that adult cells, given the right environment, can in fact divide and be grown in the laboratory.
Therapy Cell has developed a methodology that allows adult cells to divide and grow in controlled laboratory conditions. These new cells can then be used for transplantation back to damaged tissue to enact tissue and organ healing.
To date, the technology has been used for the growth and transplantation of:
Tendons and ligaments and Articular cartilage They have also applied this technology to successfully grow pancreatic cells, for treatment of diabetes, and cardiac cells for the treatment of heart disease, as well as other cell types from many other tissues.
Therapy Cells has shown that given the right culture conditions, these cell types can be grown into millions of new cells, and then successfully transplanted back into the injured tissue of the individual who has donated the cells, leading to tissue repair with one’s one cells.
The need for tissue and organ repair is growing. This is due to the continual growth of our population, coupled with individual needs to maintain good health. And, as our population grows, so does the number of older people seeking to maintain optimal activity levels.
